VENDOR COMPARISON

Limitless Life Nootropics vs Paradigm Peptide

Independent side-by-side comparison across the 1 peptides both vendors sell. Composite scores, lab quality, and verified pricing.

Limitless Life Nootropics

Research
B
Score
6.8
Peptides
14
Tests
58

14 peptides covered with 58 lab tests. BPC-157 averages 6.6 across 6 tests with consistency penalty triggered.

Limitless Life Nootropics full review →

Paradigm Peptide

Research
B+
Score
7.4
Peptides
6
Tests
54

Top Retatrutide vendor by score (9.0 across 14 tests). Strong on metabolic peptides.

Paradigm Peptide full review →

Side-by-side breakdown

PEPTIDE LIMITLESS LIFE NOOTROPICS PARADIGM PEPTIDE WINNER
Ipamorelin
7.2 B (4 tests)
9.0 A (6 tests)
Paradigm Peptide
GHK-Cu
6.5 B (5 tests)
(not sold)
Limitless Life Nootropics only
BPC-157
6.4 B (6 tests)
(not sold)
Limitless Life Nootropics only
Semaglutide
6.4 B (5 tests)
(not sold)
Limitless Life Nootropics only
Tirzepatide
(not sold)
8.4 B+ (14 tests)
Paradigm Peptide only
Retatrutide
(not sold)
7.0 B (14 tests)
Paradigm Peptide only

Which to choose

Across the 1 peptides both vendors sell, Limitless Life Nootropics scores higher on 0, Paradigm Peptide scores higher on 1, and 0 are within 0.3 points (effectively tied). Paradigm Peptide additionally sells Tirzepatide, Retatrutide; Limitless Life Nootropics does not. Limitless Life Nootropics additionally sells GHK-Cu, BPC-157, Semaglutide; Paradigm Peptide does not.

Choose Paradigm Peptide for: Ipamorelin.

Composite scores reflect lab quality, sentiment, COA transparency, reliability, and price. How we score.

Full profiles: Limitless Life Nootropics review · Paradigm Peptide review